SCHEMBL6601066

SCHEMBL6601066

CCOc1cc(-c2ccccc2)nn1CCOc1ccc(-c2cccs2)cc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 1/20 0.40
MAPT P10636 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
KDM4E B2RXH2 3/20 0.38
PPARG P37231 1/20 0.38
NCOA2 Q15596 1/20 0.38
NCOA1 Q15788 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
ALDH1A1 P00352 4/20 0.38
HPGD P15428 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SLC6A9 P48067 2/20 0.37
ADORA2A P29274 2/20 0.37
SMPD3 Q9NY59 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6601824 0.88 KDM4E (0.38) PDE5AMAPTL3MBTL1KDM4EPPARG
SCHEMBL6602280 0.83 PDE5A (0.42) PDE5AMAPTL3MBTL1KDM4EPPARG
SCHEMBL6603779 0.82 PPARG (0.41) MAPTL3MBTL1KDM4EPPARGNCOA2
SCHEMBL6616088 0.82 KDM4E (0.45) MAPTL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL6604808 0.81 TP53 (0.43) PDE5AMAPTKDM4EALDH1A1NPC1
SCHEMBL6798735 0.77 TP53 (0.40) MAPTL3MBTL1PPARGALDH1A1ADORA2A
SCHEMBL6804874 0.77 L3MBTL1 (0.40) MAPTL3MBTL1KDM4EALDH1A1HPGD
SCHEMBL6602658 0.77 HPGD (0.42) MAPTL3MBTL1NPSR1ALDH1A1HPGD
SCHEMBL6601551 0.76 LTA4H (0.45) KDM4EPPARGALDH1A1HPGDNPC1
SCHEMBL6805880 0.76 CREBBP (0.40) MAPTL3MBTL1ALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION 2004-09-16 US disclosed
EP-1432689-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS Bayer Corporation (US) 2004-06-30 EP disclosed
WO-2003027074-A1 PYRAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180891-A1 Pyrazole derivatives useful in the treatment of hyper-proliferative disorders MKI67, CDK4, FLT4 PDE5A 2055/4885MAPT 3013/4885L3MBTL1 3508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.